GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Agios Pharmaceuticals
Agios Pharmaceuticals, after selling its oncology business, focused on treating genetic diseases. Its share price reflects the commercial success of its drug for a rare form of anemia and the potential of its research platform.
Share prices of companies in the market segment - Pharma metabolism
Agios is a biotech company focused on treating rare genetic diseases. Its business consists of this segment alone. We classify it as part of the Pharma Metabolism sector, and the chart below shows the general dynamics of biotech companies, where value is determined by the success of clinical data.
Broad Market Index - GURU.Markets
Agios Pharmaceuticals is a biopharmaceutical company focused on developing treatments for genetically determined diseases. Its scientific approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Agios compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
AGIO - Daily change in the company's share price Agios Pharmaceuticals
For Agios Pharmaceuticals, a company in the field of cellular metabolism, change_co is a measure of the market's reaction to scientific data. Daily fluctuations reflect volatility associated with research progress and partnerships. This metric is a key element in building biotech valuation models on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Agios Pharmaceuticals, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with AGIO, which focuses on rare genetic diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Agios Pharmaceuticals is a biopharmaceutical company specializing in drugs for the treatment of genetic diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Agios's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Agios Pharmaceuticals
Agios is a biotech company specializing in the treatment of metabolic diseases. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall market flow.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing drugs to treat rare genetic diseases. After selling its oncology business, it has focused on a new area. The chart shows how the market is reacting to this transformation and the potential of its new scientific platform.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Agios Pharmaceuticals is a biopharmaceutical company whose stock performance is driven by the sales success of its drugs and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Agios Pharmaceuticals
Agios, a biotech company focused on treating genetically determined diseases, has monthly fluctuations reflecting sales data and clinical trial news, which is typical for biotech.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Biotech companies specializing in rare diseases frequently shift their research focus, which impacts their valuations. The dynamics of this segment, shown in the graph, reflect how the market responds to strategic shifts and scientific data. This is the backdrop against which a company like Agios Pharmaceuticals is building its new R&D pipeline.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Agios Pharmaceuticals, after selling its oncology business, has focused on rare genetic diseases. The company's shares now follow news about new drug developments, demonstrating dynamics independent of the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Agios Pharmaceuticals
Following the sale of its oncology business, Agios Pharmaceuticals has focused on treating genetically determined diseases. Its weekly share price performance reflects sales of its drug for a rare form of anemia and progress in developing new drugs, which is key to future growth.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
After selling its oncology business, Agios became a rare disease-focused company. This changed its profile, and investors now compare it to other players in this niche rather than the broader biotech sector. The chart shows how the market is evaluating this new, more focused strategy.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Agios is a biotech company focused on treating genetically determined diseases. Its success depends on research results. The chart shows how its shares are self-sufficient, often defying overall market volatility.
Market capitalization of the company, segment and market as a whole
AGIO - Market capitalization of the company Agios Pharmaceuticals
Agios Pharmaceuticals' market capitalization chart is a story of transformation. After selling its oncology division, the company shifted its focus to treating genetically determined diseases. Its share price dynamics reflect how the market views this new focus and the potential of its leading drug for treating a rare blood disorder.
AGIO - Share of the company's market capitalization Agios Pharmaceuticals within the market segment - Pharma metabolism
Agios Pharmaceuticals, after selling its oncology division, has shifted its focus entirely to treating genetically determined diseases. Its market share is based on the success of its drug for a rare form of anemia, reflecting its new strategy.
Market capitalization of the market segment - Pharma metabolism
The chart below shows the market capitalization of the biotech sector. Agios Pharmaceuticals is a pioneer in the field of cellular metabolism. After selling its oncology business, the company focused on treating rare genetic diseases. Its story exemplifies how biotech companies can successfully transform and shift their focus.
Market capitalization of all companies included in a broad market index - GURU.Markets
Agios Pharmaceuticals is focused on developing drugs to treat genetic diseases. Its market capitalization reflects its scientific approach and potential for developing targeted therapies. The chart below shows the market share of companies battling rare genetic diseases.
Book value capitalization of the company, segment and market as a whole
AGIO - Book value capitalization of the company Agios Pharmaceuticals
Agios Pharmaceuticals' book value represents the company's equity, which, after selling its oncology division, focused on treating genetically determined diseases. The chart is a story of transformation and financial resurgence, with proceeds from a major deal forming a new foundation for R&D in a new area for the company.
AGIO - Share of the company's book capitalization Agios Pharmaceuticals within the market segment - Pharma metabolism
Agios Pharmaceuticals focuses on treating genetically determined diseases. The chart shows its share of actual R&D assets. These are its research centers where research is conducted to develop first-in-class drugs for patients with rare diseases.
Market segment balance sheet capitalization - Pharma metabolism
Agios Pharmaceuticals transformed itself into a company focused on genetic diseases, reducing its capital intensity. By selling its oncology business and its commercial infrastructure, it became a more "lightweight" R&D company. In the pharmaceutical sector, this exemplifies a strategic focus on innovation rather than sales.
Book value of all companies included in the broad market index - GURU.Markets
Agios Pharmaceuticals' assets are scientific capital focused on the treatment of genetically determined diseases. The company's balance sheet reflects the value of its advanced research in cellular metabolism. The chart shows the resources invested in developing drugs for patients with rare and severe diagnoses.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Agios Pharmaceuticals
Following the sale of its oncology division, Agios Pharmaceuticals focused on rare genetic diseases. Its book value may be high due to its cash position, but its market valuation reflects investors' confidence in its ability to successfully develop and commercialize new drugs in this challenging niche.
Market to book capitalization ratio in a market segment - Pharma metabolism
Agios Pharmaceuticals is a biotech company focused on genetically determined diseases. Following the sale of its oncology business, its value lies in its new developments. This chart shows how the market values the potential of its R&D pipeline relative to the company's current cash and assets.
Market to book capitalization ratio for the market as a whole
Agios Pharmaceuticals is focused on developing drugs for genetically determined diseases. After selling its oncology business, the company focused on a narrower niche. The chart shows how the market views its new focus and the potential of its remaining drugs in development, relative to its balance sheet.
Debts of the company, segment and market as a whole
AGIO - Company debts Agios Pharmaceuticals
Agios Pharmaceuticals is focused on developing drugs to treat genetically determined diseases. Following the sale of its oncology division, the company will use the proceeds to fund research and development in its new core area. The debt strategy is part of its plan to build a portfolio of drugs for rare diseases.
Market segment debts - Pharma metabolism
Following the sale of its oncology division, Agios Pharmaceuticals has focused on genetically determined diseases. This transformation also impacts its financial strategy. This chart shows how the company is using the proceeds and managing its balance sheet to fund new R&D and achieve long-term financial sustainability.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Agios Pharmaceuticals
After selling its oncology business, Agios Pharmaceuticals focused on treating genetically determined diseases. This chart shows its financial position after the transformation. The capital structure reflects its strategy for using the proceeds to fund research and development in a new area.
Market segment debt to market segment book capitalization - Pharma metabolism
Agios Pharmaceuticals specializes in drugs for the treatment of genetically determined diseases. This chart shows the level of leverage in the rare disease drug development sector. It allows one to assess how the company uses debt to finance its research compared to other players in this high-risk but potentially profitable field.
Debt to book value of all companies in the market
Agios Pharmaceuticals specializes in rare diseases. This chart shows the level of debt for the entire economy. It allows one to assess how insulated the company's niche-focused business is from the broader macroeconomic shocks that affect the debt load of most companies in the market.
P/E of the company, segment and market as a whole
P/E - Agios Pharmaceuticals
For Agios Pharmaceuticals, which focuses on treating genetic metabolic diseases, this chart is a story of transformation. After selling its oncology business, the company focused on rare diseases. Its earnings estimate reflects investors' confidence in the success of this new strategy and the potential of its current and future drugs.
P/E of the market segment - Pharma metabolism
This chart reflects the average valuation for the biopharma sector—a benchmark for Agios. Comparing the valuation of this company, which has shifted its focus from oncology to rare diseases, with the industry average helps understand whether investors believe in the success of this transformation and value its more focused business model.
P/E of the market as a whole
After selling its oncology division, Agios Pharmaceuticals focused on treating genetically determined diseases. It's a risky but potentially highly profitable strategy. This market sentiment chart helps us understand how investors view such a radical transformation and whether they are willing to fund the company's new, more focused R&D strategy.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Agios Pharmaceuticals
Agios Pharmaceuticals focuses on developing drugs to treat genetically determined metabolic diseases. The company's valuation is based on the success of its lead drug and the potential of its other developments. This chart shows how analysts forecast future sales and profitability based on the market potential of its therapeutics.
%20P%2FE%20Agios%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Agios-Pharmaceuticals&v=1772636596129 "Chart of the company's future (projected) P/E Agios Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma metabolism
Agios Pharmaceuticals is focused on treating genetically determined diseases. After selling its oncology business, the company focused on rare diseases. Its valuation relative to other biotechs demonstrates the market's confidence in the success of this new strategy and the potential of its current developments, particularly in the treatment of thalassemia.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772636596134 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Agios Pharmaceuticals is focused on developing drugs for genetically determined diseases. After selling its oncology business, the company is focusing on new drugs. This chart shows investors' overall risk tolerance, which is crucial for biotechs in the transformation phase. It reflects whether investors are willing to believe in the new strategy and fund it.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772636596161 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Agios Pharmaceuticals
Agios Pharmaceuticals is a biopharmaceutical company focused on the treatment of genetically determined metabolic diseases. Financial results, illustrated by this chart, depend on sales of its approved drug and the success of clinical trials. The search for new treatments for rare diseases is at the core of its operations.
Profit of companies in the market segment - Pharma metabolism
Agios Pharmaceuticals is focusing on developing drugs to treat genetically determined diseases after selling its oncology business. This chart shows the financial health of biotech companies working in the field of metabolism. It helps understand how successful the strategy of focusing on rare diseases is in the current market environment.
Overall market profit
Agios Pharmaceuticals is focused on developing drugs for genetically determined diseases. After selling its oncology division, the company focused on a narrower niche. Its future depends on scientific breakthroughs, not corporate profit cycles. This chart shows the macro picture, while Agios addresses specific medical needs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Agios Pharmaceuticals
Agios Pharmaceuticals is focused on developing drugs for genetically determined diseases. After selling its oncology business, the company focused on a narrower niche. Its profit forecast reflects analysts' expectations for the commercial success of its current drug and the potential for future developments in the rare disease field.
%20profit%20of%20the%20company%20Agios%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Agios-Pharmaceuticals&v=1772636596206 "Graph of future (projected) profit of the company Agios Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Agios Pharmaceuticals is focused on developing drugs to treat genetically determined diseases. The company sold its oncology business to fully focus on this area. This chart shows forecasts for its pharmaceutical segment, allowing one to assess the potential success of the company's strategy in this highly competitive but potentially lucrative niche.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772636596208 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Agios Pharmaceuticals is a biopharmaceutical company focused on treating genetic metabolic diseases. This projected profit curve influences the investment climate in biotech. During periods of economic growth, investors are more inclined to fund long-term and risky projects, which is critical for companies developing breakthrough treatments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772636596232 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Agios Pharmaceuticals
Agios Pharmaceuticals is focused on developing drugs to treat genetically determined diseases. Following the sale of its oncology division, the company has focused on a new area. This metric reflects the market's assessment of the potential revenue from its current and future drug portfolio.
P/S market segment - Pharma metabolism
Agios Pharmaceuticals is focused on developing drugs for genetically determined diseases. This chart shows the average valuation in the metabolic drugs sector. It helps understand how investors view Agios's scientific platform and its ability to create first-in-class drugs for patients with rare and serious diseases.
P/S of the market as a whole
After selling its oncology division, Agios Pharmaceuticals focused on treating genetically determined diseases. Its main product targets a rare blood disorder. Revenue depends on the success of this drug. This chart provides investors with context, allowing them to compare the valuation of a biotech company with a single product to the overall market.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Agios Pharmaceuticals
Agios Pharmaceuticals is focused on developing drugs for genetically determined diseases. Its future revenue depends on sales of its single approved drug and the success of clinical development. This chart reflects the market's assessment of the potential peak sales of its drugs and its confidence in its scientific research.
%20P%2FS%20Agios%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Agios-Pharmaceuticals&v=1772636596307 "The graph of the company's future (projected) P/S Agios Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma metabolism
Agios Pharmaceuticals is focused on developing drugs for genetic diseases, particularly rare forms of anemia. The company sold its oncology business to focus on this niche. This chart shows how investors view the prospects of its new focus compared to other biotech companies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772636596309 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
This indicator demonstrates the market's faith in scientific breakthroughs. For Agios Pharmaceuticals, a company focused on cellular metabolism for the treatment of rare genetic diseases, it reflects an appetite for innovation. Investor optimism is essential to support long-term, risky research that could lead to the development of first-in-class drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772636596314 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Agios Pharmaceuticals
Agios Pharmaceuticals is a company focused on developing drugs to treat genetic diseases. Its first approved product is for a rare blood disorder. This chart shows the drug's sales revenue. The sales growth demonstrates successful diagnosis and treatment of patients suffering from this rare condition.
Sales of companies in the market segment - Pharma metabolism
Agios Pharmaceuticals is a biopharmaceutical company specializing in cellular metabolism for the treatment of rare diseases. This chart shows the market size it serves. Agios's success in developing drugs for genetically defined diseases demonstrates the power of personalized medicine and its potential to transform patients' lives.
Overall market sales
Agios Pharmaceuticals is a company focused on cellular metabolism for the treatment of cancer and rare genetic diseases. Its growth depends on breakthroughs in research and partnerships. This overall economic activity profile sets the tone for the biotech investment climate, influencing the influx of capital into long-term scientific projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Agios Pharmaceuticals
Agios Pharmaceuticals focuses on developing drugs to treat genetically determined diseases, particularly in the area of metabolism. Following the sale of its oncology business, the company has focused on rare diseases. This chart reflects analyst expectations for the commercial success of its current drugs and the potential for future developments in this new area.
%20sales%20of%20the%20company%20Agios%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Agios-Pharmaceuticals&v=1772636596366 "Schedule of future (projected) sales of the company Agios Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma metabolism
Agios Pharmaceuticals is a biopharmaceutical company specializing in cellular metabolism for the treatment of rare genetic diseases. This forecast reflects expectations for the metabolic disorders segment. It highlights the potential analysts see in treating the underlying causes of diseases, a key scientific approach for Agios.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772636596370 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Agios Pharmaceuticals is a company focused on cellular metabolism for the treatment of genetically defined diseases. Its future depends on successful clinical developments. The overall economic environment, illustrated in this chart, influences investor risk appetite and, consequently, the ability of biotech companies to raise capital for long-term research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772636596387 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Agios Pharmaceuticals
Agios Pharmaceuticals specializes in treating rare genetic diseases. This chart shows the company's profitability, which already includes approved drugs. Profit is generated from sales of these niche drugs, but a significant portion of the revenue is reinvested in research to expand the portfolio and help new patient groups.
Market segment marginality - Pharma metabolism
Agios Pharmaceuticals is focused on developing drugs for genetically determined diseases. Following the sale of its oncology division, the company is focusing on a new area. This chart reflects its operational structure during this transition period and allows for comparison with other biotech companies specializing in rare diseases.
Market marginality as a whole
Agios Pharmaceuticals is focused on developing drugs to treat genetically defined diseases. This overall market profitability curve does not impact its research activities. Agios's success depends on its ability to create breakthrough treatments for patients with rare diseases, where pricing is determined by the unique value of the drug, not by the overall economic situation.
Employees in the company, segment and market as a whole
Number of employees in the company Agios Pharmaceuticals
Agios Pharmaceuticals is a biopharmaceutical company focused on treating genetically determined diseases. The graph shows the team of scientists and clinicians. The headcount dynamics reflect the company's strategic focus and progress in developing new drugs following the sale of its oncology business.
Share of the company's employees Agios Pharmaceuticals within the market segment - Pharma metabolism
Agios Pharmaceuticals pioneered cellular metabolism for cancer treatment and now focuses on genetic diseases. This chart shows the percentage of leading scientists specializing in metabolic pathways and rare diseases that the company attracts. It reflects its deep scientific expertise and talent pool for developing innovative drugs.
Number of employees in the market segment - Pharma metabolism
Agios Pharmaceuticals, Inc. is a company focused on cellular metabolism for the treatment of genetically determined diseases. Its first approved product is for a rare blood disorder. This chart reflects activity in the metabolic pharmaceutical sector, showing how fundamental research into cellular processes leads to the development of breakthrough drugs.
Number of employees in the market as a whole
Agios Pharmaceuticals focuses on treating genetically determined diseases. It's a deeply science-intensive business, unaffected by cyclical economic fluctuations. Investments in such companies are a bet on long-term scientific progress. They create unique jobs for researchers whose work has the potential to radically change medicine and quality of life in the future.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Agios Pharmaceuticals (AGIO)
Agios Pharmaceuticals is focused on treating genetically determined diseases. This chart shows the company's transformation. Following the sale of its oncology business, its market capitalization per employee could change significantly, reflecting its new, more focused strategy and the market valuation of its current R&D portfolio.
%20of%20the%20company%20Agios%20Pharmaceuticals%20(AGIO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Agios-Pharmaceuticals-AGIO&v=1772636596485 "Chart of market capitalization per employee (in thousands of dollars) of the company Agios Pharmaceuticals (AGIO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Agios Pharmaceuticals (AGIO) is a company focused on developing drugs to treat genetically determined diseases, particularly rare blood disorders (pyruvate kinase deficiency). This chart shows the industry average cost per employee. It helps assess how much the market values their deep expertise in cellular metabolism and their R&D portfolio.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772636596554 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Agios Pharmaceuticals focuses on developing drugs for genetically determined diseases. This chart shows the market-wide performance metric for each employee, allowing one to assess the market premium placed on deep scientific expertise in promising areas of medicine.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772636596563 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Agios Pharmaceuticals (AGIO)
Agios Pharmaceuticals is a biopharmaceutical company focused on rare metabolic diseases. The company has an approved product. This chart shows how efficiently their team (scientists, physicians, and salespeople) generates revenue from sales of this drug. Rare disease treatments are expensive, which should be reflected in this metric.
%20Chart%20Agios%20Pharmaceuticals%20(AGIO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Agios-Pharmaceuticals-AGIO&v=1772636596574 "Company Profit Per Employee (in thousands of dollars) Chart Agios Pharmaceuticals (AGIO)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Agios (AGIO) is an R&D biotech company (genetic diseases). This chart shows the benchmark for "Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772636596596 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Agios Pharmaceuticals specializes in cellular metabolism for the treatment of rare diseases (following the sale of its oncology division). It is an R&D company with an already approved product. This chart shows how much the profit from their first drug (Pyrukynd) covers the costs of researching new ones and how effective their small, focused team is.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772636596602 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Agios Pharmaceuticals (AGIO)
Agios Pharmaceuticals focuses on developing drugs for genetically determined diseases. This chart illustrates the biotech company's transformation. It reflects its ability to bring new drugs to market, which directly impacts revenue growth generated by every employee, from researcher to sales specialist.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Agios-Pharmaceuticals-AGIO&v=1772636596615 "Sales chart per company employee Agios Pharmaceuticals (AGIO)")
Sales per employee in the market segment - Pharma metabolism
Agios Pharmaceuticals is a biotech company focused on treating rare genetic diseases in the field of cellular metabolism. This chart shows the average revenue per employee in this segment. It allows one to assess how productive Agios's team (both scientific and commercial) is compared to other companies in the orphan disease niche.
Sales per employee for the market as a whole
Agios Pharmaceuticals focuses on developing drugs for the treatment of genetically determined metabolic diseases. The company has an approved product. This chart shows how productive their team (R&D, commercial) is in generating revenue from sales of their drug for rare diseases, which requires highly specialized efforts.
Short shares by company, segment and market as a whole
Shares shorted by company Agios Pharmaceuticals (AGIO)
Agios Pharmaceuticals is focused on treating genetically determined metabolic disorders. After selling its oncology business, the company is betting on one key drug. This "single-product bet" is very risky. The chart shows the size of the bets by investors who doubt the drug's commercial potential.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Agios-Pharmaceuticals-AGIO&v=1772636596642 "Short Shares Chart for the Company Agios Pharmaceuticals (AGIO)")
Shares shorted by market segment - Pharma metabolism
Agios Pharmaceuticals is a biotech company focused on cellular metabolism for the treatment of rare genetic diseases, particularly those related to red blood cells. This chart shows the overall short position in the metabolism-focused biotech sector. Its growth reflects investor skepticism regarding the success of clinical trials in this complex field, which has seen many failures.
Shares shorted by the overall market
Agios (AGIO) is a biotech focused on rare diseases. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and shed risk. Biotech stocks, even those with stable drug revenues, often experience sell-offs when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Agios Pharmaceuticals (AGIO)
Agios Pharmaceuticals (AGIO) is a company focused on treating genetically determined metabolic diseases. They target rare diseases. This chart measures the speed and strength of price movements. It clearly shows when the company's shares are entering overbought territory (signal >70) amid positive news or when investors are overly pessimistic (signal <30) about their developments.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Agios-Pharmaceuticals-AGIO&v=1772636596670 "RSI 14 indicator chart for the company's stock Agios Pharmaceuticals (AGIO)")
RSI 14 Market Segment - Pharma metabolism
Agios Pharmaceuticals (AGIO) specializes in treating genetic diseases, particularly rare forms of anemia (pyruvate kinase deficiency). They sold their oncology business. This chart measures the pulse of the Pharma/Metabolism sector. It helps distinguish AGIO's success in their new niche from the overall "overheated" or "oversold" situation in the biotech sector as a whole.
RSI 14 for the overall market
Agios Pharmaceuticals (AGIO) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AGIO (Agios Pharmaceuticals)
Agios Pharmaceuticals is a biopharmaceutical company focused on cellular metabolism for the treatment of rare genetic diseases. Its key drug treats pyruvate kinase (PK) deficiency. This chart shows the average analyst price target based on the commercial success of this therapy.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AGIO-Agios-Pharmaceuticals&v=1772636596713 "A chart showing analyst consensus forecasts for the expected stock price. AGIO (Agios Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price AGIO (Agios Pharmaceuticals)
Agios Pharmaceuticals (AGIO) is a biopharmaceutical company that sold its oncology business and is now focusing on treating rare genetic diseases, particularly anemia. This chart shows the valuation of this reversal. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their new focus.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AGIO-Agios-Pharmaceuticals&v=1772636596724 "A chart showing the difference between the consensus forecast and the actual stock price. AGIO (Agios Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Agios Pharmaceuticals sold its oncology business to focus entirely on treating rare genetic diseases, such as pyruvate kinase deficiency. This chart shows general expectations for the metabolism sector. It reflects whether experts believe a pure-play strategy in rare diseases will be successful.
Analysts' consensus forecast for the overall market share price
Agios Pharmaceuticals (AGIO) is a biotech company focused on cellular metabolism for the treatment of rare diseases (anemia). This chart of overall market sentiment is important. Optimism = the market is willing to fund R&D. But AGIO has a product, so during a recession (pessimism), investors may appreciate the non-cyclical nature of treatment demand.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Agios Pharmaceuticals
Agios Pharmaceuticals is a biotech company that, after selling its oncology business, has shifted its focus to treating rare genetic diseases in the metabolic field. This chart evaluates their new, focused strategy. It reflects the commercial success of their first drug in this area and the potential of their R&D pipeline.
AKIMA Market Segment Index - Pharma metabolism
Agios Pharmaceuticals (AGIO) is a biotech (after the sale of its oncology business) focused on rare metabolic diseases; the company has the first approved drug (Pyrukynd) for pyruvate kinase (PK) deficiency. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does Agios' niche (rare diseases) strategy differentiate it from the average pharma company?
The AKIM Index for the overall market
Agios is a biopharmaceutical company, a pioneer in the field of cellular metabolism, focused on rare hemolytic anemias. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this scientific company, commercializing its products, fits in with the overall economic trends affecting biotech.
